Home LiteratureArticle Details
PMID: 22105171 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Valosin-containing protein and neurofibromin interact to regulate dendritic spine density.

The Journal of clinical investigation ·Vol. 121 ·No. 12 ·2011-12-00 ·Pages 4820-37

Wang HF, Shih YT, Chen CY, Chao HW, Lee MJ, Hsueh YP

Abstract

Inclusion body myopathy with Paget disease of bone and frontotemporal dementia (IBMPFD) is an autosomal dominant disorder characterized by progressive myopathy that is often accompanied by bone weakening and/or frontotemporal dementia. Although it is known to be caused by mutations in the gene encoding valosin-containing protein (VCP), the underlying disease mechanism remains elusive. Like IBMPFD, neurofibromatosis type 1 (NF1) is an autosomal dominant disorder. Neurofibromin, the protein encoded by the NF1 gene, has been shown to regulate synaptogenesis. Here, we show that neurofibromin and VCP interact and work together to control the density of dendritic spines. Certain mutations identified in IBMPFD and NF1 patients reduced the interaction between VCP and neurofibromin and impaired spinogenesis. The functions of neurofibromin and VCP in spinogenesis were shown to correlate with the learning disability and dementia phenotypes seen in patients with IBMPFD. Consistent with the previous finding that treatment with a statin rescues behavioral defects in Nf1(+/-) mice and providing further support for our hypothesis that there is crosstalk between neurofibromin and VCP, statin exposure neutralized the effect of VCP knockdown on spinogenesis in cultured hippocampal neurons. The data presented here demonstrate that there is a link between IBMPFD and NF1 and indicate a role for VCP in synapse formation.

MeSH Terms
Adenosine Triphosphatases/physiology Animals CA1 Region, Hippocampal/ultrastructure Cell Cycle Proteins/physiology Cells, Cultured/drug effects,ultrastructure Cholesterol/physiology Contracture/congenital,genetics,pathology Dendrites/metabolism,ultrastructure Frontotemporal Dementia/genetics,pathology Humans Learning Disabilities/drug therapy,genetics Lovastatin/pharmacology,therapeutic use Mice Mice, Knockout Mutation, Missense Myositis, Inclusion Body/congenital,genetics,pathology Neurofibromatosis 1/genetics,pathology,psychology Neurofibromin 1/deficiency,genetics,physiology Ophthalmoplegia/genetics,pathology Osteitis Deformans/genetics,pathology Point Mutation Protein Interaction Mapping Protein Structure, Tertiary Pyramidal Cells/drug effects,ultrastructure Rats Synapses/ultrastructure Valosin Containing Protein
Chemicals
Cell Cycle Proteins Neurofibromin 1 Cholesterol Lovastatin Adenosine Triphosphatases VCP protein, human Valosin Containing Protein Vcp protein, mouse Vcp protein, rat
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Wang Hsiao-Fang
Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan.
Shih Yu-Tzu
Chen Chiung-Ya
Chao Hsu-Wen
Lee Ming-Jen
Hsueh Yi-Ping
Supplementary Concepts
Inclusion body myopathy, autosomal dominant (Disease)
References (94)
94 references, click to expand
  1. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.
    Ann Neurol. 1991 Oct;30(4):572-80 PMID: 1789684
  2. Molecular mechanisms of dendritic spine development and remodeling.
    Prog Neurobiol. 2005 Feb;75(3):161-205 PMID: 15882774
  3. Neurofibromatosis type 1 protein and amyloid precursor protein interact in normal human melanocytes and colocalize with melanosomes.
    J Invest Dermatol. 2006 Mar;126(3):653-9 PMID: 16374483
  4. CHMP2B mutants linked to frontotemporal dementia impair maturation of dendritic spines.
    J Cell Sci. 2010 Sep 1;123(Pt 17):2943-54 PMID: 20699355
  5. VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration.
    Cell Death Differ. 2001 Oct;8(10):977-84 PMID: 11598795
  6. Neurofibromin (Nf1) is required for skeletal muscle development.
    Hum Mol Genet. 2011 Jul 15;20(14):2697-709 PMID: 21478499
  7. Neurofibromatosis in children: the role of the orthopaedist.
    J Am Acad Orthop Surg. 1999 Jul-Aug;7(4):217-30 PMID: 10434076
  8. Neurofibromin physically interacts with the N-terminal domain of focal adhesion kinase.
    Mol Carcinog. 2009 Nov;48(11):1005-17 PMID: 19479903
  9. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1.
    Nat Genet. 1994 Jul;7(3):353-61 PMID: 7920653
  10. Protein dislocation from the ER requires polyubiquitination and the AAA-ATPase Cdc48.
    Nat Cell Biol. 2002 Feb;4(2):134-9 PMID: 11813000
  11. Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone.
    Hum Mol Genet. 2010 May 1;19(9):1741-55 PMID: 20147319
  12. Nuclear translocation and transcription regulation by the membrane-associated guanylate kinase CASK/LIN-2.
    Nature. 2000 Mar 16;404(6775):298-302 PMID: 10749215
  13. NF1 tumor suppressor gene function: narrowing the GAP.
    Cell. 2001 Feb 23;104(4):593-604 PMID: 11239415
  14. Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia.
    Am J Med Genet A. 2008 Mar 15;146A(6):745-57 PMID: 18260132
  15. Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras.
    Hum Mol Genet. 2006 Apr 1;15(7):1087-98 PMID: 16513807
  16. Multiple increased osteoclast functions in individuals with neurofibromatosis type 1.
    Am J Med Genet A. 2011 May;155A(5):1050-9 PMID: 21465658
  17. Identification of forty-five novel and twenty-three known NF1 mutations in Chinese patients with neurofibromatosis type 1.
    Hum Mutat. 2006 Aug;27(8):832 PMID: 16835897
  18. Structural basis of the interaction between the AAA ATPase p97/VCP and its adaptor protein p47.
    EMBO J. 2004 Mar 10;23(5):1030-9 PMID: 14988733
  19. Recent developments in neurofibromatosis type 1.
    Curr Opin Neurol. 2007 Apr;20(2):135-41 PMID: 17351482
  20. Dendritic spines of CA 1 pyramidal cells in the rat hippocampus: serial electron microscopy with reference to their biophysical characteristics.
    J Neurosci. 1989 Aug;9(8):2982-97 PMID: 2769375
  21. ESCRT-III dysfunction causes autophagosome accumulation and neurodegeneration.
    Curr Biol. 2007 Sep 18;17(18):1561-7 PMID: 17683935
  22. Conformational changes of the multifunction p97 AAA ATPase during its ATPase cycle.
    Nat Struct Biol. 2002 Dec;9(12):950-7 PMID: 12434150
  23. Roles of VCP in human neurodegenerative disorders.
    Biochem Soc Trans. 2008 Feb;36(Pt 1):105-8 PMID: 18208395
  24. Neurofibromatosis type 1 (NF1) tumor suppressor, neurofibromin, regulates the neuronal differentiation of PC12 cells via its associating protein, CRMP-2.
    J Biol Chem. 2008 Apr 4;283(14):9399-413 PMID: 18218617
  25. Synapse loss in dementias.
    J Neurosci Res. 2010 Aug 1;88(10):2083-90 PMID: 20533377
  26. Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation.
    J Cell Biol. 1983 May;96(5):1374-88 PMID: 6404912
  27. Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.
    Bone. 2011 Jun 1;48(6):1378-87 PMID: 21439418
  28. NS21: re-defined and modified supplement B27 for neuronal cultures.
    J Neurosci Methods. 2008 Jun 30;171(2):239-47 PMID: 18471889
  29. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1.
    Curr Biol. 2005 Nov 8;15(21):1961-7 PMID: 16271875
  30. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia.
    Nat Genet. 2005 Aug;37(8):806-8 PMID: 16041373
  31. p97, a protein coping with multiple identities.
    J Cell Sci. 2003 Nov 1;116(Pt 21):4283-90 PMID: 14514884
  32. Neuronal remodeling and apoptosis require VCP-dependent degradation of the apoptosis inhibitor DIAP1.
    Development. 2011 Mar;138(6):1153-60 PMID: 21343367
  33. Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions.
    J Struct Biol. 2004 Apr-May;146(1-2):44-57 PMID: 15037236
  34. VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD.
    Autophagy. 2010 Feb;6(2):217-27 PMID: 20104022
  35. Dendritic spines: structure, dynamics and regulation.
    Nat Rev Neurosci. 2001 Dec;2(12):880-8 PMID: 11733795
  36. Neurofibromin interacts with CRMP-2 and CRMP-4 in rat brain.
    Biochem Biophys Res Commun. 2008 May 2;369(2):747-52 PMID: 18313395
  37. Bone resorption in syndromes of the Ras/MAPK pathway.
    Clin Genet. 2011 Dec;80(6):566-73 PMID: 21204800
  38. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.
    Cell. 1990 Jul 13;62(1):187-92 PMID: 1694727
  39. Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.
    J Bone Miner Res. 2010 Jul;25(7):1658-67 PMID: 20200958
  40. Phosphorylation of neurofibromin by cAMP-dependent protein kinase is regulated via a cellular association of N(G),N(G)-dimethylarginine dimethylaminohydrolase.
    FEBS Lett. 2001 Apr 6;494(1-2):48-53 PMID: 11297733
  41. Sterol-induced dislocation of 3-hydroxy-3-methylglutaryl coenzyme A reductase from endoplasmic reticulum membranes into the cytosol through a subcellular compartment resembling lipid droplets.
    J Biol Chem. 2010 Jun 18;285(25):19288-98 PMID: 20406816
  42. Exome sequencing reveals VCP mutations as a cause of familial ALS.
    Neuron. 2010 Dec 9;68(5):857-64 PMID: 21145000
  43. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein.
    Nat Genet. 2004 Apr;36(4):377-81 PMID: 15034582
  44. p97/VCP at the intersection of the autophagy and the ubiquitin proteasome system.
    Autophagy. 2010 Feb;6(2):283-5 PMID: 20083896
  45. Contribution of asymmetric synapse loss to lateralizing clinical deficits in frontotemporal dementias.
    Arch Neurol. 2001 Aug;58(8):1233-9 PMID: 11493163
  46. ER stress and diseases.
    FEBS J. 2007 Feb;274(3):630-58 PMID: 17288551
  47. A novel ATP-dependent conformation in p97 N-D1 fragment revealed by crystal structures of disease-related mutants.
    EMBO J. 2010 Jul 7;29(13):2217-29 PMID: 20512113
  48. Involvement of valosin-containing protein (VCP)/p97 in the formation and clearance of abnormal protein aggregates.
    Genes Cells. 2007 Jul;12(7):889-901 PMID: 17584300
  49. NF1 gene analysis focused on CpG-rich exons in a cohort of 93 patients with neurofibromatosis type 1.
    Hum Mutat. 2000 Sep;16(3):274-5 PMID: 10980545
  50. Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin.
    BMC Med. 2008 Jul 31;6:21 PMID: 18671844
  51. Neurofibromin, a tumor suppressor in the nervous system.
    Exp Cell Res. 2001 Mar 10;264(1):19-28 PMID: 11237520
  52. Spine architecture and synaptic plasticity.
    Trends Neurosci. 2005 Apr;28(4):182-7 PMID: 15808352
  53. Mutant valosin-containing protein causes a novel type of frontotemporal dementia.
    Ann Neurol. 2005 Mar;57(3):457-61 PMID: 15732117
  54. Neurofibromin is required for barrel formation in the mouse somatosensory cortex.
    J Neurosci. 2008 Feb 13;28(7):1580-7 PMID: 18272679
  55. Frontotemporal dementia: neuropil spheroids and presynaptic terminal degeneration.
    Ann Neurol. 1998 Jul;44(1):99-109 PMID: 9667597
  56. Dendritic spine morphogenesis and plasticity.
    J Neurobiol. 2005 Jul;64(1):47-57 PMID: 15884005
  57. AAA ATPase p97/VCP: cellular functions, disease and therapeutic potential.
    J Cell Mol Med. 2008 Dec;12(6A):2511-8 PMID: 18798739
  58. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations.
    Cell. 1990 Jul 13;62(1):193-201 PMID: 2114220
  59. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease.
    J Cell Biol. 2009 Dec 14;187(6):875-88 PMID: 20008565
  60. Association between the neurofibromatosis-1 (NF1) locus and autism in the Japanese population.
    Am J Med Genet B Neuropsychiatr Genet. 2004 Nov 15;131B(1):43-7 PMID: 15389774
  61. Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation.
    Hum Mol Genet. 2006 Jan 15;15(2):189-99 PMID: 16321991
  62. HDAC6-p97/VCP controlled polyubiquitin chain turnover.
    EMBO J. 2006 Jul 26;25(14):3357-66 PMID: 16810319
  63. SUMOylation of the MAGUK protein CASK regulates dendritic spinogenesis.
    J Cell Biol. 2008 Jul 14;182(1):141-55 PMID: 18606847
  64. Characterisation of the interaction between syndecan-2, neurofibromin and CASK: dependence of interaction on syndecan dimerization.
    Biochem Biophys Res Commun. 2010 Jan 8;391(2):1216-21 PMID: 20006588
  65. Hereditary inclusion body myopathy-linked p97/VCP mutations in the NH2 domain and the D1 ring modulate p97/VCP ATPase activity and D2 ring conformation.
    Mol Cell Biol. 2009 Aug;29(16):4484-94 PMID: 19506019
  66. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity.
    Ann Neurol. 1990 May;27(5):457-64 PMID: 2360787
  67. VCP associated inclusion body myopathy and paget disease of bone knock-in mouse model exhibits tissue pathology typical of human disease.
    PLoS One. 2010 Oct 05;5(10): PMID: 20957154
  68. Dislocation of HMG-CoA reductase and Insig-1, two polytopic endoplasmic reticulum proteins, en route to proteasomal degradation.
    Mol Biol Cell. 2009 Jul;20(14):3330-41 PMID: 19458199
  69. PKA phosphorylation and 14-3-3 interaction regulate the function of neurofibromatosis type I tumor suppressor, neurofibromin.
    FEBS Lett. 2004 Jan 16;557(1-3):275-82 PMID: 14741381
  70. Syndecan-2 induces filopodia and dendritic spine formation via the neurofibromin-PKA-Ena/VASP pathway.
    J Cell Biol. 2007 Jun 4;177(5):829-41 PMID: 17548511
  71. Synapse loss in the temporal lobe in Alzheimer's disease.
    Ann Neurol. 1993 Feb;33(2):190-9 PMID: 8434881
  72. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients.
    Science. 1990 Jul 13;249(4965):181-6 PMID: 2134734
  73. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice.
    Cancer Commun. 1991 May;3(5):141-7 PMID: 2043425
  74. Ufd1 is a cofactor of gp78 and plays a key role in cholesterol metabolism by regulating the stability of HMG-CoA reductase.
    Cell Metab. 2007 Aug;6(2):115-28 PMID: 17681147
  75. p97/p47-Mediated biogenesis of Golgi and ER.
    J Biochem. 2005 Feb;137(2):115-9 PMID: 15749824
  76. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1.
    Nature. 2002 Jan 31;415(6871):526-30 PMID: 11793011
  77. Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha.
    J Biol Chem. 1998 Feb 6;273(6):3562-73 PMID: 9452483
  78. Association study of the NF1 gene and autistic disorder.
    Am J Med Genet. 1999 Dec 15;88(6):729-32 PMID: 10581497
  79. The many ways to frontotemporal degeneration and beyond.
    Neurol Sci. 2007 Oct;28(5):241-4 PMID: 17972037
  80. ESCRT, autophagy, and frontotemporal dementia.
    BMB Rep. 2008 Dec 31;41(12):827-32 PMID: 19123971
  81. Recent advances in the genetics of amyotrophic lateral sclerosis and frontotemporal dementia: common pathways in neurodegenerative disease.
    Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R182-7 PMID: 16987882
  82. Molecular mechanisms of dendritic spine morphogenesis.
    Curr Opin Neurobiol. 2006 Feb;16(1):95-101 PMID: 16361095
  83. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects.
    Hum Mutat. 2000;15(6):541-55 PMID: 10862084
  84. Clinical manifestations and management of neurofibromatosis type 1.
    Semin Pediatr Neurol. 2006 Mar;13(1):2-7 PMID: 16818170
  85. Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations.
    J Neuropathol Exp Neurol. 2006 Jun;65(6):571-81 PMID: 16783167
  86. Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation.
    Nat Cell Biol. 2001 Aug;3(8):740-4 PMID: 11483959
  87. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.
    JAMA. 2008 Jul 16;300(3):287-94 PMID: 18632543
  88. NSF and p97/VCP: similar at first, different at last.
    FEBS Lett. 2003 Nov 27;555(1):126-33 PMID: 14630332
  89. Changes in the lipid turnover, composition, and organization, as sphingolipid-enriched membrane domains, in rat cerebellar granule cells developing in vitro.
    J Biol Chem. 2001 Jun 15;276(24):21136-45 PMID: 11264283
  90. Bipartite interaction between neurofibromatosis type I protein (neurofibromin) and syndecan transmembrane heparan sulfate proteoglycans.
    J Neurosci. 2001 Jun 1;21(11):3764-70 PMID: 11356864
  91. Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability.
    J Neurosci. 2003 Apr 15;23(8):3262-71 PMID: 12716933
  92. Lovastatin blocks N-ras oncogene-induced neuronal differentiation.
    Cell Growth Differ. 1990 Oct;1(10):499-502 PMID: 2278880
  93. Cortical synaptic changes and gliosis in normal aging, Alzheimer's disease and frontal lobe degeneration.
    Dementia. 1996 May-Jun;7(3):128-34 PMID: 8740626
  94. Vacuole-creating protein in neurodegenerative diseases in humans.
    Neurosci Lett. 2003 Jun 5;343(2):77-80 PMID: 12759168
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
1558-8238
Published
2011-12-00
Epub
2011-00-21
Pages
4820-37
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC3225986
Subset
IM
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]